Cagrilintide Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 12 to 16 weeks on-cycle (titration plus maintenance), followed by a 2 to 4 week off-cycle break; some maintenance protocols extend longer without a formal pause
• Frequency: Once weekly subcutaneous injection, on a consistent day
• Common delivery routes: Subcutaneous injection only (abdomen, thighs, or upper arms, rotated each injection)
• Key timing notes: Consistency of the day matters more than the specific time of day; choose a fixed day and stick to it

Who This Protocol Is For

Cagrilintide is a long-acting amylin analog, a synthetic version of the pancreatic hormone amylin, which the body normally releases alongside insulin to signal fullness and slow the rate at which the stomach empties. People who look into a cagrilintide protocol are almost always focused on one primary goal: meaningful, sustained weight reduction. The compound works by recalibrating appetite and satiety signaling rather than by stimulating the nervous system, which makes it appealing to those who have found appetite to be the central obstacle in their weight management efforts.

The protocol attracts a fairly broad range of users. Some are exploring cagrilintide as a standalone compound to understand how amylin-pathway signaling affects their appetite before considering combination approaches. Others are looking at it as part of the CagriSema framework, the combination of cagrilintide and semaglutide, that has produced the most significant weight-loss results in Phase III trial data. Either way, the protocol structure is slow and methodical. The titration alone takes most of the first cycle, which means this is not a compound for someone looking for a quick four-week result.

Experience level matters in a specific way here. The biggest determinant of whether someone can run this protocol successfully is GI tolerance, not peptide experience in general. Someone new to subcutaneous injections can run this protocol, but anyone with a history of significant nausea, GI sensitivity, or motility issues should approach the titration even more conservatively than the standard schedule suggests. Preferred delivery method is a simpler question: cagrilintide is subcutaneous injection only, so this is not a protocol for someone unwilling to inject.

How Is a Cagrilintide Cycle Structured?

A cagrilintide cycle has a clear shape: a slow ascending titration, a maintenance phase at a stable dose, and then an off-cycle break. The titration is not optional and is not a formality. The long half-life of the compound, roughly six and a half to eight days, means the peptide accumulates steadily in the system over weeks. Escalating the dose too quickly stacks that accumulation against a body that has not had time to adapt, and the result is the kind of nausea and GI distress that causes people to abandon the protocol entirely. The titration exists to prevent that.

Most standard protocols spend four weeks at each dose step before moving up. The total titration period, from the starting dose to a full maintenance dose, typically covers 12 to 16 weeks depending on which schedule is followed. Conservative approaches extend that to 20 weeks to prioritize GI tolerance over speed. After the titration reaches the target maintenance dose, the maintenance phase continues at that level for as long as the protocol is intended to run.

Off-cycle breaks are part of the research protocol framework, typically running two to four weeks after a completed on-cycle. Clinical trials have also run cagrilintide continuously for 26 to 68 weeks without mandated cycling breaks, treating it more like a chronic metabolic medication than a cyclable peptide. How someone structures the off-cycle depends on their goals and protocol approach, and the specific lengths are built in the app.

How Your Dose Is Determined

What moves a cagrilintide dose:

• Your goal: Cagrilintide is run for one primary purpose: weight reduction. Within that, where someone lands on the dose range depends on whether the target is moderate appetite recalibration and modest weight loss, sustained meaningful fat loss over a full cycle, or maximum efficacy alongside another compound like semaglutide. Protocols aimed at moderate outcomes tend to stabilize at the lower end of the maintenance range, while those targeting the most significant weight-loss results trend toward the higher end over a longer titration. Combination protocols cap the cagrilintide dose lower than monotherapy maximums.

• Experience level: Prior peptide experience matters less than GI history. Someone with a sensitive stomach or no prior exposure to compounds that slow gastric emptying should start at the most conservative entry point and hold each dose step for the full four weeks before considering a move up. Someone who has shown strong GI tolerance may progress more comfortably, though the minimum hold at each step remains the same regardless.

• Delivery route: Cagrilintide is subcutaneous injection only. The injection site rotation across the abdomen, thighs, and upper arms matters for consistent absorption and for avoiding local tissue reactions.

• Individual response: Two people with the same goal and the same starting point can land at different stable doses. Some reach full maintenance tolerance with minimal GI disruption. Others find a slightly lower maintenance dose sustains meaningful results with a more tolerable side-effect profile and choose to stabilize there rather than pushing to the top of the range.

The titration schedule does most of the work in determining where someone lands. The slow, step-by-step escalation is not just safety scaffolding: it is how the final dose gets discovered. Someone who rushes through the titration does not just risk side effects; they also skip the signal that would have told them where their actual optimal dose sits.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your weight-loss goal, your GI tolerance history, and whether you are running cagrilintide alone or alongside another compound, and builds your cagrilintide protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take Cagrilintide?

Cagrilintide is taken once weekly. That frequency follows directly from the compound's half-life, which runs roughly six and a half to eight days. The peptide is still pharmacologically active when the next injection is due, and once-weekly dosing keeps plasma levels stable without stacking doses beyond what the body can comfortably manage. Dosing more frequently than weekly has not been shown to improve outcomes and creates unnecessary side-effect risk given the accumulation dynamics of a compound with this half-life.

The most important timing principle is consistency of day. Choosing a specific day of the week and staying with it keeps the dosing interval stable and supports the steady-state accumulation the protocol depends on. The time of day within that chosen day is far less critical. Some protocols favor morning injections to align with natural metabolic rhythms; others work around schedules and inject in the evening. Either is acceptable. What matters is that the day does not drift week to week.

Injection site rotation is part of the weekly timing discipline. Each injection should land in a different anatomical location than the previous one, cycling through the abdomen, thighs, and upper arms. Repeatedly injecting the same spot leads to local irritation and can cause tissue changes that affect how consistently the compound absorbs.

Loading and Maintenance Phases

Cagrilintide has a genuine loading phase, but it works differently from the loading phases used for other compounds. There is no higher dose at the start. Instead, the loading phase is a slow escalation, a titration, that begins well below the eventual maintenance dose and steps up gradually over multiple weeks. Think of it less like priming a pump at full pressure and more like warming up an engine before asking it to run at operating speed.

The standard titration advances every four weeks, with that four-week minimum hold being the rule that separates successful protocols from those abandoned due to intolerable nausea. Most protocols reach the full maintenance dose sometime between week 13 and week 17. Conservative titrations targeting maximum GI tolerance can run to 20 weeks before reaching maintenance.

Once the maintenance phase begins, the dose stays stable. Maintenance is not a continuation of the escalation; it is the destination. Some people reduce slightly from the maximum titration endpoint to a level that better manages side effects while still sustaining meaningful results. One important structural point: unlike compounds where the loading phase uses a higher dose than maintenance, cagrilintide's titration and maintenance phases sit on the same ascending line. The titration is the loading phase, and maintenance is simply what happens when the escalation stops and the dose holds steady.

Off-Cycle Considerations

Off-cycle breaks are part of the research protocol framework for cagrilintide, though the rationale differs from cycling logic used for compounds that require receptor sensitivity resets or hormonal feedback breaks. The most common off-cycle period runs two to four weeks, with four weeks being the more typical figure in community and research protocols.

The off-cycle period serves a few purposes. It provides an opportunity to observe whether appetite regulation and eating behaviors established during the cycle hold without the compound's support. A break also allows any residual GI adaptation to reset before the next cycle begins.

The compound clears slowly after the last injection because of its long half-life. The first week of any break is effectively still an active pharmacological period. True off-cycle, from a pharmacokinetic standpoint, begins somewhere in the second week, which matters for understanding when appetite and hunger signals are likely to return.

As noted in the cycle structure section, clinical trials have treated cagrilintide as a chronic medication, running participants continuously without off-cycle breaks. Whether to cycle with planned breaks or extend continuously is a protocol decision that the app personalizes based on goals and intended duration of use.

What to Expect Week by Week

• Week 1 to 4: Effects during this opening phase are typically subtle. The compound is building toward steady-state levels and the dose is at its lowest step. Many people report a modest reduction in appetite, particularly in late-day hunger and the urge to snack, but the effect is rarely dramatic. Some early weight change may reflect reduced food volume and water shifts rather than fat loss. GI effects, if any, tend to be mild nausea or a sense of fullness after smaller meals, both of which typically settle within the first week or two.

• Week 5 to 8: Hunger patterns begin to shift more noticeably as the dose steps up and the compound reaches a higher steady-state level. Portion sizes commonly decrease without deliberate restriction because the satiety signal arrives earlier in a meal. More consistent early fat loss is commonly reported during this window. GI adaptation is generally more established by this phase, though the dose step can briefly resurface mild nausea.

• Week 9 to 12: For protocols using a community-standard titration, this window often corresponds to another dose escalation step and the period of most active weight reduction. Cravings for calorie-dense foods commonly decrease. Eating habits begin to shift in ways that feel less effortful than dietary restriction alone.

• Beyond week 12 and into maintenance: Weight loss continues at a steadier, more gradual pace once the maintenance dose is stable. The practical picture of a well-run cagrilintide cycle at this stage is not dramatic week-to-week drops but consistent, sustained progress: hunger genuinely quieter, meals naturally smaller, and fat loss continuing in the background without the constant mental overhead that calorie restriction usually demands. Phase III clinical data suggest monotherapy protocols have been associated with roughly ten to eleven percent total body weight loss at 26 weeks in trial participants, while combination protocols with semaglutide have shown substantially higher results over longer timeframes.

These timelines reflect Phase II and Phase III clinical data and aggregated protocol experience. Individual results vary based on dose, GI tolerance, adherence to the titration schedule, dietary context, and baseline metabolic health.

Common Protocol Mistakes

Rushing the titration. The most common and most consequential mistake is escalating the dose faster than every four weeks. Because results during the first steps can feel modest, the temptation is to accelerate toward the maintenance dose. The consequence is severe nausea, significant fatigue, and appetite suppression so abrupt that adequate calorie and protein intake becomes difficult to maintain. Most protocol abandonments trace back to a rushed titration. Hold each dose step for a minimum of four weeks before considering an upward move, regardless of how tolerable the current step feels.

Starting at too high a dose. Entering the protocol above the lowest starting point skips the adaptation window the titration is designed to create. Given the compound's long half-life and accumulation dynamics, starting too high does not feel like one slightly elevated dose; it compounds across the first two to three weeks as levels build, creating a GI burden that arrives well after the initial injection.

Dosing more than once weekly. The compound is still pharmacologically active when the next weekly injection is due. More frequent dosing accumulates it beyond the level the once-weekly pharmacokinetics are designed for and has not been shown to improve outcomes. Once weekly, on a consistent day, is the protocol. Intramuscular injection is equally off-limits: cagrilintide is formulated for subcutaneous use only, meaning the fatty tissue layer just below the skin, not the muscle beneath it.

Skipping doses or drifting the injection day. Consistency of the dosing day is what keeps plasma levels stable. Missing a dose or routinely shifting the injection day by several days disrupts the steady-state accumulation the protocol depends on. If a dose is missed by a day or two, the next injection should go on the original schedule rather than being skipped entirely.

Pushing through intolerable GI side effects instead of stepping back. When nausea, vomiting, or severe GI distress at a new dose step is significant enough to affect daily function or food intake, the right move is to return to the previous dose and stabilize for two to four weeks before retrying the escalation. Forcing through a dose step that is genuinely intolerable does not build tolerance faster; it more often ends the protocol.

Neglecting injection site rotation and combination-protocol discipline. A once-weekly injection into the same anatomical spot repeatedly causes local irritation and can produce tissue changes that affect how consistently the compound is absorbed. Rotating through the abdomen, thighs, and upper arms with each weekly injection is not optional. For anyone running cagrilintide alongside another injectable, label every vial clearly and use separate syringes for each compound; dose ranges across combination protocols can differ significantly, and confusing vials is not a minor error.

Cagrilintide is not FDA-approved for human use as of 2026 and remains under Phase III clinical evaluation. All protocols described here represent research and community-aggregated approaches rather than approved medical guidance. It is not currently identified as a prohibited substance under WADA, though its status in competitive athletic contexts should be verified against current prohibitions before use.

Frequently Asked Questions

How long is a typical cagrilintide cycle?

Most research protocols run 12 to 16 weeks on-cycle, encompassing the titration phase and a period at the maintenance dose, followed by a two to four week off-cycle break. Some maintenance protocols extend longer without a formal pause, treating the compound more like a chronic intervention. The specific cycle length that fits a particular goal and starting point is built in the MyPeptidePal Protocol Creator.

How often do you take cagrilintide?

Cagrilintide is taken once weekly via subcutaneous injection, always on a consistent day. The once-weekly frequency follows directly from the compound's half-life of roughly six and a half to eight days, which keeps plasma levels stable with a single weekly administration. More frequent dosing has not been shown to improve outcomes and is not part of any established protocol.

Does cagrilintide need a loading phase?

Yes, but not in the conventional sense of a higher starting dose. Cagrilintide uses a slow ascending titration as its loading mechanism, beginning at the lowest starting dose and stepping up every four weeks. The titration is how the compound builds to therapeutic levels gradually while giving the body time to adapt to its gastric-emptying effects.

Do you need to cycle off cagrilintide?

Research protocols commonly include a two to four week off-cycle break after a completed on-cycle, primarily to assess appetite and behavioral changes in the absence of the compound. Clinical trials, by contrast, have run cagrilintide continuously for six months to over a year without mandated breaks. Whether to cycle or extend continuously depends on goals and intended duration of use.

Can cagrilintide be combined with semaglutide?

The CagriSema combination of cagrilintide and semaglutide is one of the most studied configurations in Phase III trials and has produced substantially higher weight-loss outcomes than either compound alone. Both follow the same slow titration schedule and are administered at separate injection sites. GI adverse events are meaningfully more common in the combination than with either compound individually, which makes the titration discipline even more important in a combined protocol.

What happens when cagrilintide is stopped?

Because of the compound's long half-life, the peptide clears slowly after the last injection, with pharmacological activity continuing through roughly the first week of any off-cycle period. As levels fall, appetite and hunger signals typically return. How much of the behavioral change around eating persists after clearance varies by individual, which is one reason the off-cycle observation period is considered informative in research protocols.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for cagrilintide in one place.